Beam Therapeutics Inc

NASDAQ:BEAMUnited States

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Contact Information

Headquarters

238 Main StreetCAMBRIDGE, MA, United States 02142

Phone

857-327-8775

Fax

302-655-5049

Executives

President

Giuseppe Ciaramella

Chief Executive Officer, Principal Financial and Accounting Officer, Director

John Evans

Chief Financial Officer

Terry-Ann Burrell

Chief Medical Officer

Amy Simon

Chief Legal Officer and Secretary

Christine Bellon